Pharmacy Management

Pharmacy Management

Prescription drugs are the fastest growing component of healthcare costs. These costs can be prohibitive, requiring employers to change plan designs and shift even more cost to their employees. This is particularly true for specialty medications that typically represent 50% of drug spend from just 1-2% of drug utilizers. 

Unfortunately, many employers don’t have the purchasing power or market leverage to negotiate better pricing. It’s also challenging for employers to identify and access money saving opportunities. 

Our Alera Group Pharmacy Solutions practice has a dedicated team of experienced, in-house Pharmacy Benefits Management experts. They offer a full range of pharmacy consulting services, including:

  • Prescription drug program evaluations for clients of all sizes and industries
  • Comprehensive RFP management renewal, market check and RFI
  • PBM contract review and negotiation
  • Consultative support to identify and deploy unique cost-mitigation for specialty drug solutions
  • Data analytics that enable precise financial and clinical pharmacy benefits consulting and reporting, maximizing the plan value and employee dollars
  • All forms of pharmacy benefits auditing, including PBM contract pricing, plan design and clinical
  • On-going risk management and cost containment under our Rx Concierge Program

With Alera Group, you have a local partner and a team of experts you can rely on to help you manage pharmacy costs and improve your outcomes today and in the future.

Our Alera Group Pharmacy Solutions experts are backed by leading-edge tools and strategic solutions focused on meeting the needs and expectations of our clients through every stage of the pharmacy process.

Control pharmacy costs

From procurement to prescriptions.

Report Image
Download Now

Find an office or contact us

EXPERT EDUCATION

Events and Webinars

Employee Benefits

Setting Your Strategy for the New Year: Alera Group's 2025 Employee Benefits Market Outlook

Our experts will highlight key results from Alera Group’s "2025 Employee Benefits Market Outlook" and explain how these trends can impact your benefits program this year.

January 16, 2025 at 01:00 pm CT | Virtual

Sign Up
Webinar graphic - Alera Engage

THOUGHT LEADERSHIP

Insights

Employee Benefits

Don’t Forget About Your Gag Clause Attestations

When the Consolidated Appropriations Act, 2021 (CAA) was enacted on December 27, 2020, it included a provision that prohibits group health plans and health insurance carriers from entering into certain agreements that, either directly or indirectly, restrict the release of certain information related to provider networks and de-identified encounter data, among other things. Such restrictions are commonly referred to as “gag clauses.” The CAA also requires plans and carriers to attest annually that their agreements do not include such impermissible gag clauses.

November 20, 2024

Find out more

Employee Benefits

Avoiding an Employee Lawsuit Over a Tobacco Surcharge Claim

Tobacco surcharges on health insurance premiums for employees who use tobacco products are attractive options for employers looking to keep their workforce healthy while lowering their organization’s healthcare costs. But surcharges can go too far, and many employers may be unaware of the limitations. Alera Group's new whitepaper on tobacco surcharges is designed to assist employers in complying with federal regulations.

November 19, 2024

Find out more

Employee Benefits

Legal Alert: RxDC Reporting Due June 1

Reminder: RxDC Reporting Due June 1

With the 2023 reference year RxDC reporting deadline approaching soon, plan sponsors should familiarize themselves with recent updates to the RxDC Reporting Instructions.

March 27, 2024

Find out more

Employee Benefits

Webinar: Weight-Loss Drugs and Group Health Plans | Alera Group

Rising pharmacy costs are among the chief drivers of healthcare expenses for employers and employees, thanks largely to a surge in use of drugs you’ve seen advertised in those ubiquitous commercials. Given the cost of such drugs and their mixed record of success, employers and employees should exercise caution.

February 6, 2024

Find out more